Digital Health Breakthrough: AI-Powered Remote Drug Testing Removes Barriers to Recovery

BOSTON, Sept. 16, 2025 /PRNewswire/ -- Q2i today announced a collaboration with King's College London (King's) to evaluate its AI-powered technology, which enables accurate, remote drug testing for individuals in recovery from opioid use disorder.

Frequent in-person drug testing creates significant barriers to care. Patients are often required to visit clinics several times a week, a burden that can be overwhelming for those managing transportation difficulties, work schedules, or family responsibilities. While telehealth has expanded access to treatment, drug testing—an essential component of recovery programs—has remained difficult to administer outside of clinical settings with the accuracy providers demand.

Q2i's breakthrough technology addresses this challenge with AI-validated, at-home drug testing. Patients can complete tests from home, while providers receive secure, digitally observed results with the clinical reliability needed to support ongoing care. The system integrates seamlessly with telehealth and hybrid models, removing logistical hurdles that often disrupt recovery.

"Drug testing has traditionally been a challenge in digital health programs," said Carol Ann Getty, lead researcher at King's. "The latest advances in AI offer real benefits for both clinical teams and clients, particularly in terms of speed and reliability when it comes to digitally supervised testing. It's an innovation that helps reduce barriers to care without compromising clinical standards".

In addition to testing, Q2i's solution integrates contingency management (CM), an evidence-based approach that uses motivational incentives to encourage engagement, strengthen adherence to treatment plans, and support long-term recovery outcomes.

"We are delighted to work with King's on this important advancement," said Steven Jenkins, CEO of Q2i and recipient of the Excellence Awards CEO of the Year in Digital Health. "Our AI-powered technology is improving access in the U.S., and this collaboration underscores its international relevance. With new offices in the UK, our CM division (CMI) is positioned to expand across Europe."

By combining secure, AI-driven drug testing with proven behavioral health interventions, Q2i aims to eliminate one of the biggest obstacles to recovery. The technology is designed to make treatment more accessible, keep patients connected to care, and help sustain recovery over the long term.

Q2i develops digital health solutions that enhance engagement, adherence, and outcomes. Its platforms integrate evidence-based practices, AI technology, and mobile-first design to make treatment more accessible for patients and scalable for providers. Q2i's CM division (CMI) is recognized as a global leader in digital contingency management solutions.

SOURCE Q2I